🇺🇸 FDA
Patent

US 12036241

Compositions and methods for immune cell modulation in adoptive immunotherapies

granted A61KA61K2239/38A61K2239/48

Quick answer

US patent 12036241 (Compositions and methods for immune cell modulation in adoptive immunotherapies) held by Fate Therapeutics, Inc. expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2239/38, A61K2239/48, A61K31/4155, A61K31/517